SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

CCCX is trending as Infleqtion, its quantum technology merger target, garners significant attention for its role in a NASA space mission and a U.S. Department of Energy contract, leading to community discussion around its perceived undervaluation against quantum peers and high expectations for its upcoming merger and NYSE debut as INFQ.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is rallying following its European CE Mark approval for the Eversense 365 CGM and the first commercial integration with the twiist automated insulin delivery system, with the community highly anticipating broader adoption of its superior one-year implantable technology despite historical management concerns and ongoing market volatility.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as widespread user frustration mounts over persistent platform outages and trading restrictions, especially with its ThinkorSwim platform. Despite recent positive financial updates and a substantial share buyback program, the community is actively discussing these reliability issues and the possibility of switching to alternative brokers.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is navigating intense investor speculation ahead of its earnings report, fueling a stark divide between bulls anticipating a significant short squeeze driven by its AI lending model and critics lamenting consistent underperformance and management's perceived lack of communication. The broader fintech sector's volatility and concerns over consumer credit health continue to weigh heavily on community sentiment, making the stock a focal point for both potential rebound and further weakness.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending after a mixed earnings report, where an EPS beat was contrasted by a revenue miss and modest guidance, fueling community debate over its perceived deep value at a low forward P/E versus ongoing concerns about its balance sheet and broader fintech sector headwinds.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending higher after an analyst upgrade to Outperform, fueled by robust long-term data for its atopic dermatitis treatment demonstrating sustained efficacy and a favorable safety profile. The community is actively discussing the drug's potential across multiple autoimmune conditions, speculating on significant valuation upside, a potential acquisition, and an anticipated resolution to its legal dispute.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending amidst a sharp stock decline following its Q4 earnings report, which revealed strong revenue growth and a substantial reduction in cash burn. This has sparked significant community discussion around whether the market is overlooking the company's fundamental improvements and clearer path to profitability.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending after reporting strong quarterly results that surpassed expectations, driven by solid demand from AI and cloud customers. This performance is injecting optimism into the broader software sector, with many discussing its potential to reverse recent market apprehension.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending sharply higher following a strong earnings report that highlighted record user growth, expanding margins, and the success of its Wrapped campaign, sparking community debate over its transition from a pure growth story to a high-margin cash generator. Many users are pointing to impressive premium subscriber increases and improved profitability as reasons for the stock's significant bounce from its recent lows, viewing it as a major turning point.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital is experiencing a sharp sell-off and investor frustration following a significant earnings miss and a 50% dividend cut, aimed at stabilizing its eroding net asset value amidst a challenging CLO market. While many community members are grappling with losses and questioning management, some see the dividend reduction as a necessary long-term step to shift from a yield trap to a compounding machine.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Scales Platform-Led Digital Healthcare Access and Care

HIMS expands its tech-driven care platform with new diagnostics, AI tools and specialty treatments for personalized health.

LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat...

LifeMD (NASDAQ:LFMD) Shares Up 2.3% - Still a Buy?

LifeMD (NASDAQ:LFMD) Stock Price Up 2.3% - Here's Why...

Daily Wegovy pill brings GLP-1 weight loss treatment to U.S. adults

When I first started following news about GLP 1 drugs, everything revolved around injections that patients had to store, handle, and learn to use correctly. Now the arrival of a Wegovy pill in U.S...

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Equity

LifeMD Adds Novo Nordisk's Weight-loss Pill Wegovy To Telehealth Platform

(RTTNews) - LifeMD, Inc. (LFMD), a provider of virtual primary care and pharmacy services, on Monday said it is now offering Novo Nordisk's Wegovy pill for chronic weight management and...

LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One...

HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand

Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.

Insider Selling: LifeMD (NASDAQ:LFMD) CMO Sells 15,000 Shares of Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of...

Jessica Friedeman Sells 15,000 Shares of LifeMD (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of...

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LFMD
LifeMD Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LFMD News

LFMDLifeMD Inc